IDL Biotech wants to focus on rapid diagnostic tests and automated assays of its tumor markers. By licensing the platform ELISA to Beckman Coulter, we can focus our resources on streamlining and developing the other platforms, said Gunnar Wahlberg, CEO of IDL Biotech.
IDL Biotech announced it has signed an agreement with Beckman Coulter for licensing IDLs entire range of manual ELISA tumor markers. The licensing agreement provides Beckman Coulter with global sales rights and enables IDL to sell material for production and to receive royalties. The agreement has been formally countersigned by Immunotech, a Beckman Coulter subsidiary.
The tumor markers included in the ELISA platform are TPS®, TPAcyk, MonoTotal® and UBC®.
Read the full press release here (Swedish)